Genmab — Februar 2019
-
God morgen.
-
Bob..bob.
-
DnB Markets
We expect focus to be on the 2019 guidance, particularly Darzalex sales and related milestone payments (results due at 17:00 CET on 20 February). It looks set to meet its 2018 guidance and give conservative 2019 guidance of DKK3.5bn–3.9bn in revenue and DKK1.6bn–1.8bn in EBIT. We also expect an update on the MAIA filing. We reiterate our BUY and DKK1,540 target
-
Der var jeg for hurtigt. Det blev en bibob.
-
The multiple myeloma drug market https://www.nature.com/articles/d41573-019-00031-w
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind